Press Releases

Press Releases

Samsung Biologics becomes the first in the Korean pharma to achieve ISO 22301 Certificate

Samsung Biologics becomes the first in the Korean pharma to achieve ISO 22301 Certificate



Samsung Biologics ISO 22301 Certificate award ceremony
?

[INCHEON, KOREA] April 25, 2018 ? Samsung Biologics, one of the global biologics development and manufacturing companies, announced today that it received ISO 22301 certificate, the international standard Business Continuity Management System(BCMS), as the first Korean pharmaceutical company from BSI(British Standards Institution), a global certification association.

ISO 22301 certificate is a comprehensive standard published by the International Organization for Standardization (ISO) that represents the highest level of commitment to business continuity and disaster preparedness.

 

In the case of biopharmaceuticals, the production and supply of biologics is directly linked to the life of patients suffering from serious disease including cancer, so it is crucial to stably produce and recover from the crisis.

 

Accordingly, global pharmaceutical companies consider crisis systems critical and request a high level of crisis response system from their partners.

 

Samsung Biologics has launched internal task force composed of 16 teams and 22 people and has discovered a total of 573 projected risks for about two years, reflecting global customer’ needs.
 
Ultimately, Samsung Biologics has established an emergency response scenario by anticipating the internal and external crisis that may happen in order to obtain ISO certification.

 

Furthermore it has also proved that Samsung is able to maintain the continuity of management in a short period of time in case of unexpected emergency such as incident and disaster, by pre-setting and preparing the resources and time required to overcome the crisis.

 

“Through ISO 22301 certificate, Samsung’s quality management ability will be recognized once again and it will be a great help in order to get additional orders,” said TH Kim, CEO of Samsung Biologics. “Samsung will continue to identify internal and external risks and improve our processes so that we will become a company that leads global standards for crisis response by providing our customers with high service availability and business continuity.”

 

                                                                                                                           - The END ?

 

 

Samsung Biologics becomes the first in the Korean pharma to achieve ISO 22301 Certificate



Samsung Biologics ISO 22301 Certificate award ceremony

[INCHEON, KOREA] April 25, 2018 – Samsung Biologics, one of the global biologics development and manufacturing companies, announced today that it received ISO 22301 certificate, the international standard Business Continuity Management System(BCMS), as the first Korean pharmaceutical company from BSI(British Standards Institution), a global certification association.

ISO 22301 certificate is a comprehensive standard published by the International Organization for Standardization (ISO) that represents the highest level of commitment to business continuity and disaster preparedness.

 

In the case of biopharmaceuticals, the production and supply of biologics is directly linked to the life of patients suffering from serious disease including cancer, so it is crucial to stably produce and recover from the crisis.

 

Accordingly, global pharmaceutical companies consider crisis systems critical and request a high level of crisis response system from their partners.

 

Samsung Biologics has launched internal task force composed of 16 teams and 22 people and has discovered a total of 573 projected risks for about two years, reflecting global customer’ needs.
 
Ultimately, Samsung Biologics has established an emergency response scenario by anticipating the internal and external crisis that may happen in order to obtain ISO certification.

 

Furthermore it has also proved that Samsung is able to maintain the continuity of management in a short period of time in case of unexpected emergency such as incident and disaster, by pre-setting and preparing the resources and time required to overcome the crisis.

 

“Through ISO 22301 certificate, Samsung’s quality management ability will be recognized once again and it will be a great help in order to get additional orders,” said TH Kim, CEO of Samsung Biologics. “Samsung will continue to identify internal and external risks and improve our processes so that we will become a company that leads global standards for crisis response by providing our customers with high service availability and business continuity.”

 

                                                                                                                           - The END –

 

 

SITE MAP

close
Close

Your download is ready

Click Download.

Close

Subscribe to Our Newsletter

Please fill in your details, select one or more areas of interest, and click the subscribe button to receive our newsletter.

Subscribe to Our Newsletter
  • Privacy Policy to collect the email address that I have provided until I withdraw my consent. The collected information will only be used for the purpose of mailing service. If you do not wish to consent, you will not be able to receive the newsletter. Samsung Biologics respects the privacy of its subscribers.
Close

Please fill out the form
to view the full content

Please sign up to view the post..
* Required
Privacy Policy
close

SECURITY REPORT

Your valuable comments contribute to protecting Samsung Biologic’s core technology and management information, as well as reinforcing domestic competency and economic development.

  • This page is created for reporting core technology and management information leakage.
  • The reported contents as well as the identity of the reporter are strictly secured.
THE MANUAL FOR SECURITY NOTIFICATION